Expert Opinion on Biological Therapy · 2008 · 33 citations · 32 references
MedicineOncologyPharmacologyBreast OncologyCardio-oncologyMolecular OncologyAdjuvant TherapyAnthracycline CardiotoxicityBreast Cancer PharmacotherapyCancer Therapy-related CardiotoxicityHer2-positive Breast CancerHer2-targeted Therapy CardiotoxicityAdjuvant Therapy CardiotoxicityAnthracycline-induced CardiomyopathyAnthracycline-induced CardiotoxicityAnti-her2 Therapy CardiotoxicityBreast Cancer PrognosisComparative Clinical TrialsDisease-free Survival AssessmentMechanisms Of Cardiac Injury
BACKGROUND: Trastuzumab has significantly improved the prognosis of breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2). This result has been achieved in all disease settings, by increasing overall survival in early stage and advanced disease and by increasing pathological complete responses in neoadjuvant disease. OBJECTIVE: Although the greatest impact of this monoclonal antibody has been seen in the adjuvant setting, by increasing disease-free survival and overall survival rates an increased rate of both symptomatic and non-symptomatic cardiac toxicity has also been observed. METHODS: In the following review, the different mechanisms of trastuzumab cardiac toxicity are described and, in addition, the clinical data coming from both trials and meta-analyses is discussed. RESULTS: While there is strong evidence for the incidence of trastuzumab-related cardiac toxicity, there is still little known on the exact pathogenesis of this toxicity. Interestingly, both experimental and clinical data suggest that trastuzumab may sensitize cardiomyocytes to injuries and stress from administration of anthracyclines. This has led to a proposed novel mechanism of cardiotoxicity that appears to be quite different from the anthracycline-associated cardiotoxicity. Trastuzumab does not seem to cause any overt ultrastructural abnormality; it does, however, lead to myocardial dysfunction. CONCLUSION: Most of the proposed hypotheses seems to be related to the activity of trastuzumab in interfering with the ERBB-2 receptor. Indeed, data from clinical trials in the adjuvant setting report increased cardiac toxicity in those patients who previously received anthracyclines.
32
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2008 · 10.2K citations · Full text
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17